In recent years, the FDA has demonstrated a too-cozy relationship with the pharmaceutical industry and an attitude of shielding rather than disclosing information, ... The opportunity to name a new commissioner is a chance to take the agency in a necessary new direction ... and reassert that the agency's top priority is what's good for John Q. Public when it comes to reviewing drugs in the marketplace.